



18th June, 2020

The Manager
BSE Limited
Corporate Relationship Department
P. J. Towers, Dalal Street,
Mumbai – 400 001.

The Manager
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051.

BSE Scrip Code No. 524280

NSE Symbol : KOPRAN

Sub : Updates

Dear Sir/Madam

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Active Pharmaceutical Ingredients Manufacturing facility at Mahad of Kopran Research Laboratories Limited, a 100 percent subsidiary of Kopran Limited was inspected by the USFDA in January 2019 without any observation under Para 483. This was notified to the Stock Exchange on 25th January 2019.

The Company had filed the DMF of Atenolol which has now been approved by the USFDA and the Company can commence supplies of the API Atenolol to the US market.

Kindly disseminate the information on the Exchange website.

Regards,

For Kopran Limited

Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS 3897



KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111
Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078.
Works:• Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337• Fax: (02192) 274025